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Cannabinoid CB2 receptor (CB2R) stimulation delays
rubrospinal mitochondrial-dependent degeneration
and improves functional recovery after spinal cord
hemisection by ERK1/2 inactivation
L Latini1,4, E Bisicchia1,4, V Sasso1, V Chiurchiù1,2, V Cavallucci1, M Molinari*,1, M Maccarrone1,3,5 and MT Viscomi*,1,5
Spinal cord injury (SCI) is a devastating condition of CNS that often results in severe functional impairments for which there are
no restorative therapies. As in other CNS injuries, in addition to the effects that are related to the primary site of damage, these
impairments are caused by degeneration of distal regions that are connected functionally to the primary lesion site. Modulation
of the endocannabinoid system (ECS) counteracts this neurodegeneration, and pharmacological modulation of type-2
cannabinoid receptor (CB2R) is a promising therapeutic target for several CNS pathologies, including SCI. This study examined
the effects of CB2R modulation on the fate of axotomized rubrospinal neurons (RSNs) and functional recovery in a model of
spinal cord dorsal hemisection (SCH) at the cervical level in rats. SCH induced CB2R expression, severe atrophy, and cell death
in contralateral RSNs. Furthermore, SCH affected molecular changes in the apoptotic cascade in RSNs – increased cytochrome c
release, apoptosome formation, and caspase-3 activity. CB2R stimulation by its selective agonist JWH-015 significantly
increased the bcl-2/bax ratio, reduced cytochrome c release, delayed atrophy and degeneration, and improved spontaneous
functional recovery through ERK1/2 inactivation. These findings implicate the ECS, particularly CB2R, as part of the endogenous
neuroprotective response that is triggered after SCI. Thus, CB2R modulation might represent a promising therapeutic target that
lacks psychotropic effects and can be used to exploit ECS-based approaches to counteract neuronal degeneration.
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Spinal cord injury (SCI) is a devastating neurological disease
that results in severe functional impairments for which there
are no restorative therapies. In addition to the primary injury,
functional impairments following SCI are attributed to degen-
erative events in regions that are remote but functionally
connected to the primary lesion site – that is, supraspinal
structures. These events include cell death and structural
changes and are important predictors of outcome.1,2
However, few studies have examined the molecular and
biochemical changes in remote neurons after SCIs as targets
for therapeutic interventions.
The spinal cord hemisection (SCH) model is a sensitive and
reliable paradigm that has been used to evaluate forelimb
motor functions and changes in remote supraspinal areas that
are functionally related to the primary site of injury.3 When
performed at the cervical level, an SCH in rodents axotomizes
nearly the entire contralateral neuronal population of the
magnocellular component of the red nucleus and mimics
Brown–Séquard syndrome in humans.3,4
The endocannabinoid system (ECS) is a ubiquitous lipid
signaling system that has homeostatic functions and
comprises two types of G protein-coupled receptors,
CB1R and CB2R, their endogenous ligands (arachidonoyl
ethanolamide or anandamide and 2-arachidonoylglycerol),
and the enzymatic machinery responsible for their synthesis
and degradation.5 In the brain, the ECS acts like a
neurotransmitter system that governs neuronal excitability
at various synapses, regulating such processes as pain,
mood, appetite, memory, and motor activity.6,7 Unlike
classical neurotransmitters, endocannabinoids are not
stored in vesicles but are produced on demand in response
to various stimuli.6,7
The ECS is modulated by many neurological insults, such
as cerebral ischemia,8 traumatic,9 and focal brain injury,10 and
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it is increasingly considered a promising therapeutic target in
several CNS pathologies9–13 including SCI.14–17
After an incomplete SCI by concussion, the rapid postle-
sional activation of cannabinoid receptors that occurs is
considered an endogenous protective mechanism.14 Simul-
taneous stimulation of CB1R and CB2R early before injury
impedes expansion of the lesion and white matter at the
epicenter of damage – effects that are maintained for up to 28
days after injury.15 This limited damage is also accompanied
by greater recovery of locomotor function.16 These neuropro-
tective effects are prevented by simultaneous blockade of
CB1R and CB2R but not of either receptor alone. In the same
SCI model, Adhikary et al.17 demonstrated that a selective
CB2R agonist significantly modulated immune responses at
the lesion site and improved motor and autonomic functions.
The potential of endocannabinoids to limit damage at the
primary site has also been highlighted in many studies.8,9,14–17
Recent reports have implicated the ECS in remote damage,10
but the function of the ECS in supraspinal structures after SCI
has not been examined.
In this study, we determined the effects of CB2R modulation
on the fate of the axotomized rubrospinal neurons (RSNs) and
on spontaneous functional recovery after SCH at the cervical
level in rats. Beginning 7 days after damage, SCH induced
severe atrophy and cell loss and upregulated CB2R in
axotomized RSNs. Notably, neuronal degeneration pro-
ceeded concomitantly with molecular changes in the apoptotic
cascade – that is, greater cytochrome c (cyt-c) release from
damaged mitochondria, cyt-c/Apaf-1 binding, and caspase-3
activity. CB2R stimulation by its selective agonist JWH-015
(JWH) significantly increased the bcl-2/bax ratio, reduced cyt-
c release, delayed atrophy and degeneration, and improved
spontaneous functional recovery through ERK1/2 inactiva-
tion. Thus, CB2R modulation is a therapeutic target that might
counteract the remote degeneration of supraspinal regions
after SCI.
Results
SCH modulates the expression of CB2R in axotomized
rubrospinal neurons. We examined CB1R and CB2R
expression in the red nucleus (RN) of unlesioned (CTRL)
and lesioned (SCH) animals by quantitative real-time PCR
(qPCR) and western blot. In the RN of CTRL animals, CB1R
and CB2R were nearly absent, based on mRNA and protein
levels (Figures 1a and b). SCH did not modify CB1R
expression over time (Figures 1a and b).
In contrast, SCH significantly upregulated CB2R mRNA
and protein at 7 days after injury (Figures 1a and b) that
declined at 21 days, nearly reaching CTRL levels at 60 days
after injury (Figures 1a and b). Consistent with our biochem-
ical results, we noted strong induction of CB2R in the RN of
SCH animals by immunohistochemistry.
To avoid difficulties in limiting RN borders after SCH
because of axotomy-induced cell shrinkage, RSNs were
retrogradely labeled by Fast-blue (FB) injection at C5/C6 on
the right side of the cord (see Materials and Methods). In the
RN of SCH animals, CB2R was expressed almost exclusively
by FB-positive neurons, confirming the neuronal phenotype
and spinal projection of these cells (Figure 1c). In CTRL
animals,B90% of RSNs were FB positive, but did not express
CB2R (Figure 1d). At 7 days after SCH, B75% of RSNs that
were FB positive expressed CB2R, roughly 15% were FB
positive and CB2R negative, and the remaining cells were FB
negative and CB2R positive (Figure 1d). Notably, at subse-
quent time points, we observed a progressive decline in
FB/CB2R positivity and a parallel rise in FB/CB2R negativity in
RSNs (Figure 1d).
Mitochondrial damage accompanies RSN atrophy and
degeneration. SCH induces progressive and severe shrink-
age of RSN bodies.18,19 Consistent with this finding, at 7
days after SCH, axotomized RSNs shrank, and their cross-
sectional area decreased compared with CTRL (Figure 2a).
By FB/Nissl staining, the reduction in area was accompanied
by a progressive loss of RSNs, based on stereological RSNs
cell counts. The effects of SCH on RSNs were expressed as
the ratio of the number of RSNs after SCH to that of RSNs of
unlesioned animals (CTRL) – that is, the experimental/
unlesioned (E/C) ratio. From days 7 to 60, the E/C ratio fell
from B70 to B48 (Figure 2b).
The response of RSNs to SCH has been debated by many
groups over whether axotomy primarily induces atrophy or cell
death.20,21 We stained dissociated RSNs with NeuN and LIVE/
DEAD to measure neuronal cell count and death, respectively,
at various stages after SCH. By cytofluorimetric analysis, we
noted a decrease in neuronal cells in SCH and greater cell
death, confirming our morphological data. At 7 days after SCH,
we observed significant neuronal loss (Figure 2c) and a
concomitant increase in dying cells (Figure 2d). As the lesion
progressed, neuronal loss reached 50% and cell death
increased by B60% after 60 days of SCH (Figure 2d).
To characterize the cellular events that are affected by
SCH, we examined the involvement of apoptosis in inducing
the morphological changes in RSNs. Mitochondria are significant
in the initiation of apoptosis,22 and the release of cyt-c from
damaged mitochondria is a crucial pro-apoptotic factor.23
At 7 days post SCH, the majority of FB-positive RSNs had
intense and diffuse cyt-c immunostaining into the cytosol that
was absent in FB-positive RSNs of CTRL, indicating cyt-c
release from damaged mitochondria (Figure 2e).
Consistent with the immunohistochemical data, at 7 days
after the lesion, SCH significantly increased the cytosolic cyt-c
fraction as observed by western blot of the mitochondrial–
cytosolic protein fractionation (Supplementary Figure 1) that
leveled out at subsequent time points (Figure 2f).
Next, we examined the apoptotic pathway downstream of
cyt-c release. By co-immunoprecipitation, the binding between
cyt-c and Apaf-1 rose significantly after SCH compared with
CTRL (Figure 3a), concomitant with decreased binding
between Apaf-1/hsp70 and Apaf-1/hsp90 (Figure 3b). The
cyt-c/Apaf-1 interaction returned to prelesion levels at
later time points, and the Apaf-1/hsp70 and Apaf-1/hsp90
associations weakened progressively (Figure 3b).
Caspase-3 activation is an irreversible step in the commit-
ment of a cell toward apoptosis.24 Thus, we examined the
apoptotic pathway downstream of apoptosome formation to
determine the fate of axotomized neurons. Caspase-3 activity
differed between 7 and 21 days post SCH (Figure 3c), falling
to prelesion values at the last time point.
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CB2R stimulation after SCH reduces atrophy and delays
rubrospinal neuronal loss. To determine the function of
CB2R upregulation in RSNs after SCH, we modulated CB2R
pharmacologically by administering a selective CB2R agonist
(JWH) or antagonist (SR144528 (SR2)) SCH (Figure 4a)
and to CTRL and SCH animals (Supplementary Table 1).
After 7 days of treatment, animals were killed immediately
(Figure 4b) or after 14 (Figure 4c) or 53 days (Figure 4d).
By quantitative analysis of RSN cross-sectional area, the
mean area of RSNs was 477 mm2 in all groups of unlesioned
saline-treated controls (CTRL-sal). Similar results were
obtained for unlesioned JWH-treated (CTRL-JWH, 481 mm2)
and SR2-treated (CTRL-SR2, 484mm2) controls. Thus, the
mean area of unlesioned saline-treated control cells was used
as the reference. Data from SCH groups are reported as a
percentage versus the CTRL-sal area.
After SCH, cell size declined in all experimental groups. The
CB2R agonist JWH had a significant protective effect on RSN
cell size (Figure 5a). At all time points considered, there were
significant differences in RSN cell area between SCH-sal and
Figure 1 Spinal cord hemisection induces cannabinoid receptor (CBR) expression in contralateral red nucleus. (a and b) CB1R and CB2R mRNA and protein levels in
control unlesioned animals (CTRL) and after spinal cord hemisection (SCH) at various time points after damage (7, 14, 21, and 60 days), expressed as percentage of CTRL.
(c) Triple-labeled and merged confocal images of CB2R (red), Fast-blue (FB; gray), and NeuN (green) in red nucleus of control (CTRL) and 7 days after SCH. (d) Histogram of
percentages of CB2R-positive, FB-positive, and CB2R/FB double-positive neurons in CTRL and SCH at various times after damage. Data are expressed as mean±S.D.
(n¼ 5/group). One-way ANOVA followed by Bonferroni multiple comparison tests. *Po0.05; **Po0.01 versus CTRL. Scale bars: 20mm
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SCH-JWH (Figure 5a), whereas RSN area of SCH-SR2 and
SCH-sal groups did not differ significantly. Nevertheless,
RSNs in the SCH-SR2 group tended to decrease in size
(Figure 5a).
JWH also mitigated RSN cell loss (Figure 5b). Indeed,
at all time points considered, there were significant differences
in treatment effect on the E/C ratio between SCH-sal and
SCH-JWH and between SCH-SR2 and SCH-JWH (Figure 5b),
whereas E/C ratio of SCH-SR2 and SCH-sal groups did not
differ significantly. Nevertheless, E/C ratio in the SCH-SR2
group tended to decrease (Figure 5b).
CB2R stimulation increases the bcl-2/bax ratio and
decreases cyt-c release from damaged mitochondria.
Cell death and survival following CNS injury can result
from alterations in the intracellular balance between
pro- and anti-apoptotic factors, of which the bcl-2/bax ratio
is an important component.25 After SCH, the bcl-2/bax
ratio in the RN, as expected, fell significantly, but CB2R
activation by JWH influenced the SCH-induced changes in
bcl-2/bax ratio. At 7 and 21 days after injury, the SCH-JWH
group had significantly higher bcl-2/bax ratios compared
with the SCH-sal and SCH-SR2 groups (Figure 5c).
Conversely, no significant differences were observed
between the SCH-sal and SCH-SR2 groups. At 60 days,
the bcl-2/bax ratio was similar in all SCH groups
(Figure 5c).
These data were confirmed by analysis of cyt-c release
from damaged mitochondria of RSNs into the cytosol.
SCH-JWH animals released less cyt-c than SCH-sal and
Figure 2 Spinal cord hemisection induces degenerative changes in axotomized red nucleus. (a) Histograms of soma sizes of magnocellular rubrospinal neurons at various
time points after SCH (7, 14, 21, and 60 days), expressed as percentage of unlesioned (CTRL) area. (b) Histograms of stereological counts of FB/Nissl-stained RSNs neurons
at various time points after SCH (7, 14, 21, and 60 days), expressed as experimental/unlesioned (E/C) ratio. (c) Flow cytometry histograms of NeuN-positive cells in RN at
various time points after SCH (7, 14, 21, and 60 days), expressed as percentage of CTRL. (d) Flow cytometry histograms of Live/Dead-positive cells, expressed as percentage
of CTRL. (e) Confocal images from red nucleus of CTRL and SCH animals at 7 days after damage stained with Fast-blue (blue) and reacted with NeuN (red) and cytochrome c
antibodies (green). (f) Representative immunoblots and densitometric graphs of cytosolic levels of cytochrome c in RN of CTRL and SCH animals at various time points after
damage (7, 14, 21, and 60 days). Data are expressed as mean±S.D. (n¼ 5/group). One-way ANOVA followed by Bonferroni multiple comparison tests. *Po0.05;
**Po0.01; ***Po0.001 versus CTRL. Scale bars: 50mm
CB2R in remote SCI damage
L Latini et al
4
Cell Death and Disease
SCH-SR2 animals at 7 and 21 days (Figure 5d). At 60 days,
the level of cyt-c release was similar in all SCH-treated groups
(Figure 5d).
CB2R stimulation improves spontaneous functional
recovery after SCH. Following SCH, as in earlier reports,
the animals had a closed forepaw on the injured side and
uncoordinated overground locomotion. No deficits were
observed in the forelimb on the contralateral side.
Motor performance was analyzed by beam-walking test at 0
(CTRL), 1, 3, and 5 days and by catWalk at 7, 21, and 60 days.
The beam-walking data are shown in Figure 6a. At 1 day after
SCH, the SCH-Sal, SCH-JWH, and SCH-SR2 groups
experienced uniform, severe motor impairments (Figure 6a).
From day 3, SCH-JWH animals had better beam-walking
scores than the SCH-sal and SCH-SR2 groups (Figure 6a).
No differences on score were observed between SCH-sal and
SCH-SR2 (Figure 6a).
CatWalk data are reported in Figures 6b–f. All SCH
groups developed clear deficits in all parameters on day 7.
In subsequent days, all groups generated recovery curves
that never reached control values. However, the SCH-JWH
findings differed significantly from the SCH-sal or SCH-SR2
data at all time points. No differences were observed between
the SCH-sal and SCH-SR2 data (Figures 6b–f).
These data demonstrate that CB2R stimulation significantly
improves spontaneous functional recovery after SCH.
CB2R stimulation protects rubrospinal neurons by
ERK1/2 inactivation. Having demonstrated the positive
effects of JWH on cell area and survival as well as on
functional recovery, we addressed the question of which
signaling pathway might be responsible for CB2R-mediated
neuroprotection.
In various cell death paradigms, CB2R can trigger
phosphorylation cascades that involve ERK1/2 and p38
and c-Jun N-terminal kinase (JNK) and phosphoinositide
3-kinase (PI3k)/Akt signaling.10,26 Evaluation of the phos-
phorylation status of ERK1/2, p38, JNK, and PI3k/Akt in
CTRL and SCH animals treated with saline or with a CB2R
agonist or a CB2R antagonist showed that the activation of
p38, JNK, and PI3k/Akt was neither affected by the lesion nor
after CB2R modulation (data not shown). Conversely, the
phosphorylation of ERK1/2 was significantly increased in
SCH group compared with CTRL (Figure 7a) and CB2R
stimulation caused ERK1/2 dephosphorylation, whereas
Figure 3 Spinal cord hemisection induces mitochondrial-dependent apoptosis in rubrospinal neurons. (a) Representative immunoblotting and densitometry
of Apaf-1-precipitated cyt-c expression in CTRL and SCH animals. (b) Representative immunoblotting and densitometry of Apaf-1-precipitated hsp-70 and
hsp-90 expression in CTRL and SCH animals after damage (7, 14, 21, and 60 days). (c) Time course of caspase-3 activity in RN of CTRL and after SCH (7, 14, 21, and
60 days). Data are expressed as mean±S.D. (n¼ 5/group). One-way ANOVA followed by Bonferroni multiple comparison tests *Po0.05; **Po0.01; ***Po0.001;
versus CTRL
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CB2R inhibition caused an increase of ERK1/2 phosphoryla-
tion (Figure 7a).
To determine the role of ERK1/2 signaling in CB2R
stimulation effects, we irreversibly inhibited ERK1/2 by
intracerebroventricularly injecting PD98059 at 30 min before
SCH (SCH-PD; Supplementary Table 1). PD98059 treatment,
as expected, induced ERK1/2 inactivation after SCH
(Supplementary Figure 2). Notably, after SCH, inactivation
of ERK1/2 was associated with a significant reduction of RSN
atrophy (Figure 7b), higher neuronal survival (Figure 7c),
higher bcl-2/bax ratios (Figure 7d), reduction of cyt-c release
(Figure 7e), and greater functional recovery (Figures 8a–f) as
compared with saline-treated SCH group.
Consistent with the neuroprotective role of CB2R-mediated
ERK1/2 inactivation after SCH, no differences on RSN
atrophy (Figure 7b), neuronal survival (Figure 7c), bcl-2/bax
ratios (Figure 7d), cyt-c release (Figure 7e), and functional
recovery (Figures 8a–f) were observed between JWH and PD
treatments.
Discussion
This study has demonstrated: (1) de novo induction
of CB2R in RSNs after SCH; and, under selective CB2R
agonism (2) attenuation of RSN atrophy and cell loss;
(3) increase in bcl-2/bax ratio in the RN; (4) decrease in cyt-c
release; and (5) improvement in functional recovery; and
finally (6) all CB2R neuroprotective effects are ERK1/2
dependent.
The SCH model is a sensitive and reliable paradigm for
evaluating supraspinal changes after spinal damage.3,4
Degeneration occurs in distal areas that are functionally
related to the primary site of injury – a phenomenon that is
termed ‘remote damage’2 that influences postlesional
impairments.27
After lesions develop in their axons, the intracellular
machinery of RSNs rearranges, wherein cytoskeletal
proteins, regeneration-associated genes, and neuronal
nitric oxide synthase (nNOS) expression modulate.26,28,29
Figure 4 Schematic of spinal cord hemisection (SCH) model and of experimental protocols employed in the study. (a) Because of the crossed organization of the
rubrospinal tracts, a right cervical hemisection axotomizes virtually all neurons of the contralateral red nucleus (RN) that were labeled by a single injection of the retrograde
tracer Fast-blue (FB) performed at level C5/C6 at 10 days before spinal cord hemisection at the C3/C4 level. (b–d) After spinal cord hemisection (SCH; day 0), CTRL
(unlesioned rats) and SCH rats were divided into three groups and treated with saline (SCH-sal), JWH-015 (SCH-JWH), or SR144528 (SCH-SR2) for 7 days and killed (b)
immediately after treatment; (c) 14 days after treatment (day 21); and (d) 53 days after treatment (day 60)
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In contrast, less is known about changes in receptor
expression patterns. Our data demonstrate that CB2R
expression, although it is absent under physiological condi-
tions, is induced by axonal damage in RSNs, peaking at 7
days post lesion, and subsequently fading. The transient
CB2R peak can be interpreted taking into account that, after
axotomy, different systems are active transitorily, each one in
precise time windows. Within remote damage models, it is
worth recalling that a similar sequential time pattern has been
reported in the hemicerebellectomy (HCb) model.10
Figure 5 JWH-015 delays SCH-induced rubrospinal neuron degeneration. (a) Histograms of soma sizes of magnocellular rubrospinal neurons in SCH-saline (SCH-sal),
SCH-JWH-015 (SCH-JWH), and SCH-SR144528 (SCH-SR2) at 7, 21, and 60 days after injury (see Materials and Methods). Soma area is expressed as percentage of
unlesioned (CTRL) area. (b) Histograms of stereological counts of FB/Nissl-stained rubrospinal neurons, expressed as experimental/unlesioned (E/C) ratio, in SCH-saline
(SCH-sal)-, SCH-JWH-015 (SCH-JWH)-, and SCH-SR144528 (SCH-SR2)-treated groups at 7, 21, and 60 days after injury (see Materials and Methods). (c) Flow cytometry
histograms of NeuN-positive cells in RN of SCH-saline (SCH-sal)-, SCH-JWH-015 (SCH-JWH)-, and SCH-SR144528 (SCH-SR2)-treated groups at 7, 21, and 60 days after
injury expressed as percentage of CTRL. (d) Flow cytometry histograms of Live/Dead-positive cells in SCH-saline (SCH-sal)-, SCH-JWH-015 (SCH-JWH)-, and SCH-
SR144528 (SCH-SR2)-treated groups at 7, 21, and 60 days after injury expressed as percentage of CTRL. (e) Representative immunoblots and densitometric graphs of time
course of bcl-2/bax ratio in red nucleus of CTRL and SCH-saline (SCH-sal)-, SCH-JWH-015 (SCH-JWH)-, and SCH-SR144528 (SCH-SR2)-treated animals at 7, 21, and 60
days after injury. Intensities of bcl-2 and bax bands are expressed as bcl-2/bax ratio. (f) Representative immunoblots and densitometric graphs of time course of cytochrome c
release (cytc) in red nucleus of CTRL and SCH-saline (SCH-sal)-, SCH-JWH-015 (SCH-JWH)-, and SCH-SR144528 (SCH-SR2)-treated animals at 7, 21, and 60 days after
injury. Data are expressed as mean±S.D. (n¼ 5/group). Two-way ANOVA followed by Bonferroni multiple comparison tests. *Po0.05; **Po0.01; ***Po0.001
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Changes in CB2R expression occur in many models. In
primary lesion sites of traumatic and vascular brain injuries
and in SCIs, only glial cells have been reported to experience
altered CB2R expression.14,30,31 In distal areas, CB2R levels
modulate in neurons in a cerebellar model of remote
damage.10,32 CB2R expression in neurons remains
debated.33–35
In this study, CB2R was lacking from unlesioned animals,
consistent with the general model of low or absent CB2R
expression in the brain. Conversely, the upregulation of CB2R
after development of a lesion in remote neurons, but not
astrocytes or microglial cells, contrasts with what has been
reported in the primary lesion site after SCI, traumatic brain
injury (TBI), and vascular insults.14,30,31
Following SCH, RSNs enter a chronic injury state, and the
relationship between atrophy and cell death has been largely
debated.20,21 Axotomized neurons progress through an
orderly series of morphological changes, including shrinkage,
atrophy, and eventually death,18,19,21 as reported in RSNs
after cervical axotomy by several groups.21,36–38 Never-
theless, whether cells die or merely become atrophic remains
unknown. Axotomized RSNs evolve in a chronic atrophic state
with cell death only at very late stages;20,39 yet, studies
suggest that axotomy by SCH affects a significant and
progressive loss of RSNs.21,36–38,40 This dispute is relevant
with regard to timing neuroprotective and regenerative
interventions, in which the demonstration that the number of
RSNs decreases after SCH is a critical issue, wherein
counting method, species, and age might account for these
discrepancies.
The cell loss that we observed, based on unbiased
stereology methods and cytofluorimetry, supports previous
reports of RSN death after SCH.21,36–38,40 Despite the
significance of the atrophy/death dilemma, the intracellular
cascades in RSNs after SCH that might address this issue
have not been studied. In this report, we examined axotomy-
induced neuronal death in RSNs by characterizing key
elements of the apoptotic cascade: cyt-c release, apopto-
some formation, and caspase-3 activation. All of these indices
confirmed SCH-induced activation of the mitochondrial-
dependent apoptotic cascade in RSNs. Beginning on day 7
after SCH, significant amounts of cyt-c were released into the
cytosol, inducing apoptosome formation, as evidenced
by Apaf-1/cyt-c binding that in turn mediated caspase-3
Figure 6 JWH-015 treatment improves functional recovery after SCH. (a) Long-term evaluation of scores in beam-walk test of unlesioned (CTRL) and SCH-saline
(SCH-sal)-, SCH-JWH-015 (SCH-JWH)-, and SCH-SR144528 (SCH-SR2)-treated animals. (b) Long-term evaluation of print length, expressed in mm of right forepaw in
unlesioned (CTRL) and SCH-saline (SCH-sal)-, SCH-JWH-015 (SCH-JWH)-, and SCH-SR144528 (SCH-SR2)-treated animals measured with catWalk. (c) Long-term
evaluation of print width measure (mm) of right forepaw in unlesioned (CTRL) and SCH-saline (SCH-sal)-, SCH-JWH-015 (SCH-JWH)-, and SCH-SR144528 (SCH-SR2)-
treated animals measured with the catWalk. (d) Long-term evaluation of print area (mm2) of right forepaw in unlesioned (CTRL) and SCH-saline (SCH-sal)-, SCH-JWH-015
(SCH-JWH)-, and SCH-SR144528 (SCH-SR2)-treated animals measured with the catWalk. (e) Long-term evaluation of Max contact area (mm2) of right forepaw in unlesioned
(CTRL) and SCH-saline (SCH-sal)-, SCH-JWH-015 (SCH-JWH)-, and SCH-SR144528 (SCH-SR2)-treated animals measured with the catWalk. (f) Long-term evaluation of
regularity index expressed as percentage in unlesioned (CTRL) and SCH-saline (SCH-sal)-, SCH-JWH-015 (SCH-JWH)-, and SCH-SR144528 (SCH-SR2)-treated animals
measured with the catWalk. Data are expressed as mean±S.D. (n¼ 10/group). Two-way ANOVA followed by Bonferroni multiple comparison tests. **Po0.01; ***Po0.001
SCH-JWH versus SCH-sal; ##Po0.001; ###Po0.0001 SCH-JWH versus SCH-SR2
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activation, indicating the commitment of RSNs irreversibly
toward apoptotic cell death. These data indicate that at this
stage cell commitment is already established, indicating, in
contrast to previous reports,20,41 the importance of the earlier
events, namely before day 7 after SCH, to correctly tailor
neuroprotection.
Most therapeutic approaches for SCI limit the development
of secondary damage through neuroprotective measures for
acute SCI.42 Nevertheless, the supraspinal centers are
considered to be crucial for recovery. To this end, various
strategies that target RSNs have been tested.41,43–45
Our study has demonstrated novel neuroprotective effects
of CB2R stimulation on RSNs after SCH. Selective CB2R
activation by JWH reduced SCH-induced atrophy and cell loss
by delaying RSN degeneration.
The treatment was administered for 7 days, and data were
collected immediately and 14 and 53 days after treatment
suspension. Significant neuroprotective effects were appar-
ent immediately after cessation and maintained at all
subsequent points. Nevertheless, in a comparison with
untreated lesioned animals, the slope of the degeneration
curve was similar in all groups, suggesting that CB2R-
mediated neuroprotection delays but does not halt degenera-
tion. After JWH treatment was withdrawn, the degenerative
phenomena recommenced. The delay-effect hypothesis is
confirmed by the bcl-2/bax ratio and cyt-c release data.
CB2R modulation of these indices is high immediately after
suspension of the treatment but declines at day 21 and
disappears at day 60, consistent with reactivation of the
apoptotic cascade.
CB2R-dependent anti-apoptotic effects have been
seen in various in vitro46 and in vivo models of neuronal
damage.10,32,47 Most data implicate mitochondrial protection
as the most significant factor of CB2R-mediated neuro-
protection,10,32 for which PI3k/Akt signaling, bcl-2, and
hsp70 are key elements that remain undefined. CB2R-
mediated neuroprotection, at least in the in vivo model of
HCb, requires interactions with the nitric oxide (NO) system.32
In this model, nNOS inhibition blocks its neuroprotective
effects. These aspects have not been examined in SCH.
Nevertheless, previous data on nNOS upregulation in RSNs
after SCH26 suggest that similar CB2R/NO interactions can
also occur in this model.
After brain damage, different signaling mechanisms oper-
ate to account for the variety of the retrograde responses
occurring after injury,27 all requiring the involvement of
sophisticated mechanisms that link signaling systems with
intracellular transport machineries.
CB2R is able to signal through ERK, JNK, and p38 and
phosphatidylinositol-3 kinase (PI3K).10,48 In the present study
we showed that CB2R-mediated neuroprotection occurred
through ERK1/2 pathway, whereas the other major signaling
routes were not involved. CB2R stimulation selectively
changed SCH-induced ERK1/2 activation. In particular,
CB2R stimulation counteracted the lesion-induced effects by
reducing ERK1/2 phosphorylation, whereas CB2R antagonist
treatment tended to highly maintain the SCH-induced ERK1/2
activation. The importance of ERK1/2 signaling in neuropro-
tection was further sustained by treatment with a selective
ERK1/2 inhibitor (PD98059). Pretreatment with PD98059
Figure 7 CB2R mediates neuroprotection through ERK1/2 dephosphorylation. (a) Representative immunoblots and densitometric graphs of ERK1/2 phosphorylation
(pERK1/2) in red nucleus of CTRL, SCH-saline (SCH-sal)-, SCH-JWH-015 (SCH-JWH)-, and SCH-SR144528 (SCH-SR2)-treated animals at 7 days after injury.
(b) Histograms of soma sizes of magnocellular rubrospinal neurons in SCH-saline (SCH-sal), SCH-JWH-015 (SCH-JWH), and PD98059 (SCH-PD) at 7 days after injury (see
Materials and Methods). Soma area is expressed as percentage of unlesioned (CTRL) area. (c) Histograms of stereological counts of FB/Nissl-stained rubrospinal neurons,
expressed as experimental/unlesioned (E/C) ratio, in SCH-saline (SCH-sal)-, SCH-JWH-015 (SCH-JWH)-, and SCH-PD98059 (SCH-PD)-treated groups at 7 days after injury.
(d) Representative immunoblots and densitometric graphs of time course of bcl-2/bax ratio in red nucleus of SCH-saline (SCH-sal)-, SCH-JWH-015 (SCH-JWH)-, and
SCH-PD98059 (SCH-PD)-treated animals at 7 days after injury. Intensities of bcl-2 and bax bands are expressed as bcl-2/bax ratio. (e) Representative immunoblots
and densitometric graphs of time course of cytochrome c release (cyt-c) in red nucleus of SCH-saline (SCH-sal)-, SCH-JWH-015 (SCH-JWH)-, and SCH-PD98059
(SCH-PD)-treated animals at 7 days after injury. Data are expressed as mean±S.D. (n¼ 5/group). One-way ANOVA followed by Bonferroni multiple comparison tests.
**Po0.01; ***Po0.001
CB2R in remote SCI damage
L Latini et al
9
Cell Death and Disease
reduced all lesion-induced effects, namely RSN atrophy and
cell death (Figures 7b and c), cyt-c release (Figure 7e), and
improved functional recovery (Figures 8e and f).
The present data converge in indicating ERK1/2 as the
signaling route through which CB2R mediates neuroprotec-
tion in SCH. This pathway is quite different from the one
demonstrated to funnel neuroprotective CB2R signal after
HCb, namely PI3k/Akt.10 In spite of the different intracellular
signaling, in both models, CB2R stimulation prevents axot-
omy-dependent mitochondrial failure. Why CB2R will execute
its neuroprotective functions through PI3k/Akt or ERK1/2
pathway according to the cell type remains to be defined.
Nevertheless, it is worth recalling that in other models,
stimulus and, particularly, cell type have been shown to be
critical in determining which signaling is triggered by
cannabinoid receptor stimulation.49
The neuroprotective effects of CB2R have been
observed in different brain injury models,10,50,51 for which
various mechanisms have been proposed. In stroke the
CB2R immunomodulatory effect has been considered
preeminent,50,51 whereas CB2R has anti-apoptotic effects
on central neurons in a model of HCb.10 In SCI models,
CB2R has immunomodulatory effects on primary
lesions16,17 and anti-apoptotic effects on areas of remote
damage (present study). Thus, although the complex
mechanisms that are mediated by the ECS after brain
lesions cannot be defined based on current data, the
significance of ECS signaling in life–death decisions is
evident in many brain pathologies.
After incomplete SCI, animals spontaneously recover
locomotor function,52 and in our model, untreated SCH
rats recovered gait progressively. CB2R stimulation, in
parallel with the delay in degeneration, improves sponta-
neous recovery, based on our beam-walking and
catWalk data. Nevertheless, establishing a causal link
between sparing neuronal death and improving functional
recovery is difficult. Recovery after SCI requires rearrange-
ments at many levels in the spinal and supraspinal
Figure 8 PD98059 treatment improves functional recovery after SCH. (a) Long-term evaluation of scores in beam-walk test of SCH-saline (SCH-sal)-, SCH-JWH-015
(SCH-JWH)-, and SCH-PD98059 (SCH-PD)-treated animals. (b) Long-term evaluation of print length, expressed in mm of right forepaw in SCH-saline (SCH-sal)-, SCH-JWH-
015 (SCH-JWH)-, and SCH-PD98059 (SCH-PD)-treated animals measured with catWalk. (c) Long-term evaluation of print width measure (mm) of right forepaw in SCH-saline
(SCH-sal)-, SCH-JWH-015 (SCH-JWH)-, and SCH-PD98059 (SCH-PD)-treated animals measured with the catWalk. (d) Long-term evaluation of print area (mm2) of right
forepaw in SCH-saline (SCH-sal)-, SCH-JWH-015 (SCH-JWH), and SCH-PD98059 (SCH-PD)-treated animals measured with the catWalk. (e) Long-term evaluation of Max
contact area (mm2) of right forepaw in SCH-saline (SCH-sal)-, SCH-JWH-015 (SCH-JWH)-, and SCH-PD98059 (SCH-PD)-treated animals measured with the catWalk.
(f) Long-term evaluation of regularity index expressed as percentage in SCH-saline (SCH-sal)-, SCH-JWH-015 (SCH-JWH)-, and SCH-PD98059 (SCH-PD)-treated animals
measured with the catWalk. Data are expressed as mean±S.D. (n¼ 5/group). One-way ANOVA followed by Bonferroni multiple comparison tests. #Po0.05; **Po0.001;
***Po0.0001 SCH-sal versus SCH-PD
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circuits, and the effects of CB2R modulation might differ
between centers and cell types – neuronal or glial – by time
and location. Functional recovery after SCI is a complex
phenomenon that is not limited to a single brain structure or
intracellular signaling pathways,53 hence requiring further
study aimed at unraveling the underlying interactions
between different brain structures and multiple signaling
pathways.
Materials and Methods
Animals and spinal cord hemisection. Adult male Wistar rats
(200–250 g) were obtained from Harlan (Udine, Italy) and maintained in our
animal facilities on a 12 : 12-h light/dark cycle, receiving food and water ad
libitum. Animals were handled in accordance with the guidelines published in
the NIH Guide for the Care and Use of Laboratory Animals, the principles laid
out in the Guidelines for the Use of Animals in Neuroscience Research
published by the Society for Neuroscience, and European Union guidelines
(Council Directive 86/609/EEC). Protocol was approved by Italian Ministry of
Health. Special care was taken to use the minimum number of animals required
for statistical accuracy. For surgical procedures, the rats were deeply
anesthetized by intraperitoneal (i.p.) injections of Rompun (xylazine, 20 mg/
ml, 0.5 ml/kg; Bayer, Milan, Italy) and Zoletil (tiletamine and zolazepam,
100 mg/ml, 0.5 ml/kg; Virbac, Milan, Italy).
At 10 days before lesion, animals underwent a right-side C5/C6
intraspinal injection of FB to retrogradely label the cervical projecting
neurons of the RN (Figure 4a). For this purpose, hair overlying the cervical
vertebrae was removed, the skin was treated with betadine and incised, and the
layers of muscle were bluntly dissected. The dura was removed using blunt
iridectomy scissors and fine forceps and a right-side C5/C6 intraspinal injection of
5ml of 2% FB (Sigma, St. Louis, MO, USA; F5756) was performed. After FB
injection, the muscles were sutured in layers and the skin was closed with wound
clips. After 10 days, animals underwent spinal cord injury surgery. After anesthesia
(as above), the skin was treated with betadine and incised, and the layers of muscle
were bluntly dissected. A dorsal unilateral laminectomy was performed at C4 to
expose the dura-covered spinal cord. The dura was removed using blunt iridectomy
scissors and fine forceps. Vertebral segment C4 (corresponding to spinal segment
C3/4) was identified by counting of vertebral spines from segment T2. Using sharp
iridectomy scissors, a lateral SCH was performed. To ensure the completeness of
the injury, a 30-gauge needle was swept through the injury site. Muscle and skin
layers were repaired using 5-0 vicryl sutures and rats were allowed to recover on a
heated blanket before being returned to their home cage. Control (CTRL) animals
received only a dorsal unilateral laminectomy at C4 to expose the dura-covered
spinal cord.
After surgery, animals received an analgesic (2.5 mg per subcutaneous injection
of Rimadyl; Pfizer, New York, NY, USA) once per day for 5 days and antibiotics
(1.25 mg/250 g body weight intraperitoneal injection of Baytril; Bayer) once per day
for 3 days. Animal weights were recorded daily for a week post surgery, and twice a
week thereafter. Bladder function was also assessed for 7 days post surgery, but
every animal retained bladder function postoperatively and no expressions were
necessary. The animals were monitored for hydration and eventual infections until
the end of the experiment. SCHs were histologically verified postmortem.
Incompletely injured or overhemisected rats were subsequently eliminated from
our study.
Drug treatment. The following CB2R agonist and antagonist, respectively,
were used: JWH (3 mg/kg, i.p./daily; Tocris, Bristol, UK) and SR2 (3 mg/kg,
i.p./daily; Cayman Chemicals, Ann Arbor, MI, USA). Furthermore, the selective
ERK1/2 inhibitor PD98059 (Cell Signaling, Danvers, MA, USA) was injected
intracerebroventricularly (2ml; 200mM) 30 min before damage in SCH-sal group.
Treatments in the different experimental groups are shown in detail in
Supplementary Table 1.
In the present study, three different treatment protocols were employed:
(1) CTRL and SCH animals were treated for 7 days with JWH, SR2, or saline and
killed immediately after the end of treatment (Figure 4b); (2) CTRL and SCH animals
were treated for 7 days with JWH, SR2, or saline and killed after 14 days of
treatment suspension (day 21; Figure 4c); and (3) CTRL and SCH animals were
treated for 7 days with JWH, SR2, or saline and killed after 53 days of treatment
suspension (day 60; Figure 4d).
Histology and immunohistochemistry. Rats were perfused transcar-
dially with 250 ml of saline followed by 250 ml of 4% paraformaldehyde
in a phosphate buffer (PB; 0.1 M; pH 7.4) under anesthesia induced
by i.p. injection of sodium pentobarbital (60 mg/kg). Each brain and spinal
cord was removed immediately, post-fixed in the same fixative for 2 h and,
after three washes in PB, transferred to 30% sucrose in PB solution at 41C
until they sank. Brains and spinal cords were cut into four series of
30 mm-thick transverse sections by means of a freezing microtome and were
collected in PB.
To investigate the cellular population that expressed CB2R, sections
presenting FB-positive neurons were incubated overnight with a cocktail of
primary antibodies, including rabbit anti-CB2R (1 : 200; Abcam, Cambridge, UK)
and mouse anti-NeuN (1 : 200; Millipore, Billerica, MA, USA). All primary antibody
solutions were prepared in PB and 0.3% Triton X-100 and were incubated
overnight. Each incubation step was followed by three 5-min rinses in PB.
Afterwards, sections were incubated for 2 h at RT with a cocktail of secondary
antibodies, including Alexa Fluor 488-conjugated donkey anti-mouse (1 : 200;
Invitrogen, Monza, Italy) and Alexa Fluor 543-conjugated donkey anti-rabbit
(1 : 200). Sections were examined under a confocal laser scanning microscope
(Zeiss LSM700, Oberkochen, Germany) equipped with four laser lines: violet
diode emitting at 405 nm (for DAPI), argon emitting at 488 nm, and helium/neon
emitting at 543 nm and 633 using a 40 / 0.5 NA oil objective. Images were
exported in TIFF format, contrast and brightness were adjusted, and final plates
were composed with Adobe Illustrator CS3 (San Jose, CA, USA) or Corel Draw 9
(Ottawa, ON, Canada).
Neuronal cross-sectional area measurement. For the measurement
of neuronal cross-sectional area, Nissl staining was performed on sections
presenting FB-positive neurons. As atrophy of rubrospinal neurons is recognized
to make the borders of the axotomized RN less distinct,20 FB retrograde labeling
was used as an anatomical reference for demarcating the magnocellular RN.
Quantification of RSN cell size and cell number was performed using five alternate
sections of 30-mm regularly spaced throughout the entire RN rostrocaudal
extension. Only neurons identified by a clear nuclear profile were included for
analysis. RSN mean cell area was expressed as percentage of RNS mean cell
area of CTRL animals.
Stereological analyses. To assess the extent of cell loss in RN following
SCH, stereological cell count of FB/Nissl-stained RSNs, identified by a clear
nuclear profile, was performed. To better appreciate the effects of SCH
on RSN cell loss, we related the number of surviving RSNs to the number of
neurons present in the RN of unlesioned animals (CTRL), here indicated as
E/C index.
Quantitative analyses were limited to the RN of the experimental side
projecting to the lesioned spinal cord. Using the Stereo Investigator System
(MicroBrightField Europe e.K., Magdeburg, Germany), an optical fractionator,
stereological design was applied to obtain unbiased estimates of total
Nissl-stained and FB-positive neurons. A stack of MAC 5000 controller modules
(Ludl Electronic Products, Ltd, Hawthorne, NY, USA) was configured to interface
an Olympus BX 50 microscope (Olympus, Tokyo, Japan) with a motorized stage
and a HV-C20 Hitachi color digital camera (Hitachi, Tokyo, Japan) with a Pentium
II PC workstation. A three-dimensional optical dissector counting probe (x, y, z
dimension of 30 30 10 mm, respectively) was applied. The RN was outlined
using the 4 objective and FB was used as an anatomical reference for
demarcating the magnocellular RN, although whereas the 100 oil immersion
objective was used for marking the neuronal cells. Total number of RSNs was
estimated according to the formula given below:
N ¼ SQ1=ssf1=asf1=tsf
where SQ represents the total number of neurons counted in all optically sampled
fields of the RN, ssf is the section sampling fraction, asf is the area sampling
fraction, and tsf is the thickness sampling fraction.
Fluorometric assay of caspase-3 activity. After RN isolation, tissues
were homogenized in lysis assay buffer containing 100 mM Hepes (Sigma,
H4034), pH 7.4, 0.1% Chaps (Sigma, 3023), 1 mM EDTA (Sigma, E5134),
10 mM DTT (Sigma, D9779), and 1 mM PMSF (Sigma, 7626), and lysed by
subsequent freezing in liquid N2 and thawing at 371C three times. After
centrifugation at 11 500 g for 5 min, the protein concentration of resulting
supernatant was quantified, and proteins were incubated at 371C in lysis assay
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buffer containing 50 mM Ac-DEVD-AMC (BD PharMingen, San Jose, CA, USA;
556449). The fluorescence was measured at an excitation and emission
wavelength of 380 and 460 nm, respectively, as previously described.54
Caspase-3 activity in the SCH animals was expressed as percent increase in
absorbance relative to CTRL animals.
Mitochondrial and cytosolic fraction. RNs were homogenized in Buffer
A (320 mM sucrose, 1 mM EDTA, 50 mM TRIS-HCl, pH 7.4, 1 mM DTT, and 1 mM
PMSF), with protease inhibitor cocktail (Sigma, P8340) by 30 strokes with a glass
Pyrex micro homogenizer (Sigma). The homogenate was centrifuged at 1000 g
for 10 min and the resulting supernatant was centrifuged at 10 000 g for 20 min
to obtain the mitochondrial pellet and the supernatant. The mitochondria-
containing pellet was washed three times with Buffer B (250 mM sucrose, 1 mM
EGTA, Sigma, E3889, 10 mM TRIS-HCl, pH 7.4) by centrifugation for 10 min at
10 000 g. The supernatant was centrifuged at 100 000 g for 1 h to generate
the cytosolic fraction.
Western blotting. RNs were homogenized in lysis buffer (320 mM, sucrose,
10% glycerol, 50 mM NaCl, 50 mM TRIS-HCl, pH 7.5, 1% Triton X-100, and
1 mM PMSF) with protease inhibitor cocktail (Sigma, P8340), incubated on ice
for 30 min, and centrifuged at 13 000 g for 20 min. The total protein content of
resulting supernatant was determined. Proteins were applied to SDS-PAGE and
electroblotted on a PVDF membrane. Immunoblotting analysis was performed
using chemiluminescence detection kit. The relative levels of immunoreactivity
were determined by densitometry using the software ImageQuant 5.0 (GE
Healthcare, Little Chalfont, UK). Samples were incubated with the following
primary antibodies: mouse anti-cyte-c (1 : 1000; BD PharMingen, Oxford, UK);
rabbit anti-CB1R (1 : 500; Cayman Chemicals); rabbit anti-CB2R (1 : 1500;
Cayman Chemicals); rabbit anti-bcl-2 (1 : 500; Santa Cruz Biotechnologies,
Santa Cruz, CA, USA); mouse anti-bax (1 : 2000; Santa Cruz Biotechnologies);
rabbit anti-hsp70 (1 : 500; Santa Cruz Biotechnologies); mouse anti-hsp90
(1 : 1000; Santa Cruz Biotechnologies); rat anti-Apaf-1 (1 : 2000; Millipore);
rabbit anti-ERK1/2 (1 : 1000; Immunological Sciences); rabbit anti-phospho
ERK1/2 (1 : 1000; Immunological Sciences, Rome, Italy); rabbit anti-Akt
(1 : 1000; Cell Signaling); rabbit-anti-phospho Akt (1 : 500; Cell Signaling);
mouse anti-JNK (1 : 1000; Santa Cruz Biotechnologies); mouse anti-phospho-
JNK (1 : 1000; Santa Cruz Biotechnologies); mouse anti-p38 (1 : 1000; Cell
Signaling); mouse anti-phospho-p38 (1 : 1000; Cell Signaling); and mouse anti-
GAPDH (1 : 5000; Abcam). Densities of protein bands in the western blots were
measured, and mean ratios between proteins and GAPDH were reported as
percentage of control values.
Quantitative real-time PCR. RNA was extracted from RNs using TRIzol
reagent (Invitrogen). Any remaining genomic DNA was eliminated with RNase-
Free DNase Set (Qiagen, Germantown, MD, USA) according to the
manufacturer’s instructions. Then, 1 mg of total RNA was used for RT reaction
by using the SuperScript VILOTM cDNA Synthesis Kit (Invitrogen). The following
RT-PCR program was used: 251C for 10 min, 421C for 60 min, and 851C for 5 min.
The expression of the different primers was assessed by quantitative RT-PCR
(qRT-PCR) using SensiMixTM SYBR Kit (Bioline, London, UK) as fluorescent dye
to monitor cDNA amplification. The following PCR program was used: 951C for
10 min, 40 cycles at 951C for 5 s, and 601C for 100 s. The primers used were: rat
CB1R F (50-GTTCCTCACAGCCATCGACA-30); rat CB1R R (50-CACATCAGG
CAAAAGGCCAC-30); rat CB2R F (50-TGACCGCTGTTGACCGATAC-30) and rat
CB2R R (50-CGAGAGGACCCACATGACAC-30); and GAPDH F (50-GGACCA
GGTTGTCTCCTGTG-30) and GAPDH R (50-CATTGAGAGCAATGCCAGCC-30).
GAPDH was used as housekeeping gene for quantity normalization. Then, 1ml of
first strand of cDNA product was used for amplification (in triplicate) in a 20 ml
reaction solution, containing 10 ml of iQTM SYBR Green Supermix (Bio-Rad,
Hercules, CA, USA) and 1mmol of each primer. The following PCR program was
used: 951C for 3 min, 40 amplification cycles at 951C for 10 s, 561C for 20 s, and
721C for 30 s. Fold change was determined by using the 2DDCT method.
Co-immunoprecipitation. RNs were processed in lysis buffer (20 mM Tris
HCl, pH 7.4, 1% Tx100, 150 mM NaCl, 1 mM EDTA, 5 mM MgCl2, 1 mM PMSF,
and 1% Protease Inhibitor Cocktails (Sigma)). The lysate was centrifuged for 5 min
at 41C (800 g), supernatant was recovered and centrifuged for 30 min at 41C
(10 000 g), and protein content was quantified by Bradford’s colorimetric assay
(Bio-Rad).
The protein A-Agarose (Roche, Basel, Switzerland) was washed three times in
lysis buffer and incubated for 45 min at 41C with 150 mg proteins and 500 ml of
20 mM Tris HCl, pH 7.4, 1% Tx100, 150 mM NaCl, 1 mM EDTA, 5 mM MgCl2,
1 mM PMSF, and 1% Protease Inhibitor Cocktails (Sigma). After centrifugation
for 3 min at 41C (10 000 g), 1 mg of anti-Apaf-1 was added to the supernatant
and incubated overnight at 41C. Beads were finally washed three times with lysis
buffer and co-immunoprecipitated proteins were released by boiling in SB
(2% SDS, 20% glycerol, 100 mM Tris-HCl, pH 6.8, 100 mM dithiothreitol).
Percoll isolation. RNs collected from CTRL and SCH animals (at 7, 14, 21,
and 60 days after injury) were incubated with a digestion buffer containing 1
Hanks’ Balanced Salt Solution (HBSS; 14185, Gibco, Grand Island, NY, USA),
1 mM L-Cystein (168149, Sigma-Aldrich, St. Louis, MO, USA), 30 mg/ml papain
(P4762, Sigma-Aldrich), and 0.21% deoxyribonuclease I (DNase I; D5319, Sigma-
Aldrich) in 371C water bath for 30 min and then mechanically dissociated by
trituration. Cells were washed two times with Tris-buffered saline (TBS) and then
resuspended in 8 ml of 25% of Stock Isotonic Percoll (SIP), prepared by mixing
nine parts of Percoll (17-0891-01, GE Healthcare, Piscataway, NJ, USA) with 1
part of 10 HBSS, and overlaid with 2 ml of 1 HBSS in 15 ml conical tubes.
The tubes were centrifuged at 400 g at 221C for 25 min and then the whitish
puffy layer (separated cells) was removed. After two washes in TBS, pelleted cells
were collected and processed for flow cytometry analysis. The method employed
in the present study was adapted from Juan et al.55
Flow cytometry. After Percoll isolation, cells were washed with PBS and then
stained with Alexa-488 conjugated anti-NeuN specific antibody (1 : 100; Millipore)
at 41C for 15 min in order to selectively identify neuronal cells. For staining of dying
cells, NeuN-positive cells were also stained with LIVE/DEAD dye (Invitrogen
Molecular Probes, Monza, Italy) at 4 1C for further 10 min and analyzed within 2 h.
Flow cytometry analysis of RNs was performed on a FACSCanto cytofluorimeter
(Becton Dickinson, Franklin Lakes, NJ, USA).
Beam-walking test. Animals were examined with a fine-motor test paradigm
(beam-walking test) and at 0 and 1, 3, 5, 7, 21, and 60 days after surgery. In the
fine-motor behavior test, the locomotion of the rats was evaluated preoperatively
and postoperatively using a beam-walking task with an elevated narrow beam
(150 cm long 2.5 cm wide). The worst score (‘0’) was given if the rat was unable
to traverse the beam and could neither place the affected limbs on the horizontal
surface nor maintain balance. A score of ‘1’ was given if the rat was unable to
traverse the beam or to place the affected limbs on the horizontal surface of the
beam but was able to maintain balance. A score of ‘2’ was given if the rat was
unable to traverse the beam but placed the affected limbs on the horizontal
surface of the beam and maintained balance. A score of ‘3’ was given if the rat
used the affected limbs in less than half of its steps along the beam. A score of ‘4’
was given if the rat traversed the beam and used the affected limbs to aid with
450% of its steps along the beam.
A score of ‘5’ was given if the rat traversed the beam and used the affected limbs
to aid with o50% of its steps along the beam. A score of ‘6’ was given if the rat
traversed the beam normally with no more than two-foot slips. The week before,
surgery animals were trained to run the narrow beam for a food reward once daily, 5
days per week. All the animals in all groups underwent the motor behavior test to
ensure that their performance score before surgery (day 0) was 6.
CatWalk. To assess the effects of SCI on locomotor gait dynamics, we used
the catWalk gait analysis system (version 8.1; Noldus, Wageningen, The Nederlands)
as previously described.56 Briefly, this system consists of a glass runway with
customized lighting that is video recorded as the animals traverse the runway. From
these videos, the system determines the percentage of usage by each paw and the
intensity of footprints during maximum paw contact at every step. Animals were
trained for 5 min daily in the week preceding lesion. Rats were trained to run across
the runway consistently for 5 days before testing, with each training session
consisting of 3 runs across the platform. After that animals were tested on days 0, 7,
21, and 60 postoperatively. At each experimental time point, three runs for each
animal were recorded from below the glass by a digital video camera.
Coordination and different individual paw parameters were assessed to quantify
functional recovery after treatment. The following parameters were considered:
 Regularity index (expressed in percentages): index of the number of normal step
sequence patterns relative to the total number of paw placements. It is a percent
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index and is used as a measure of the degree of interlimb coordination during the
gait cycle;
 Paw length, width, and area (in millimeter) of the forepaw during the stance
phase reflecting the total print size of the forepaw;
 maximal area (expressed in square millimeter): maximal contact area of the
forepaw at the moment of its maximal floor contact during stance.
Statistical analysis. All values were expressed as mean±S.D. Differences
between means were analyzed using one-way ANOVA or two-way ANOVA with
Bonferroni post hoc test. All statistical analyses were performed using Prism-5
software (GraphPAD Software for Science, San Diego, CA, USA) with significance
set at Po0.05.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. This work was supported by Italian Ministry of Health
(Ricerca Corrente; to M Molinari); by Wings for Life Spinal Cord Research
Foundation (to MTV); partially by International Foundation for Research in
Paraplegia (IFP) (to MTV); by program Young Researchers of Italian Ministry of
Health (GR10.184; to MTV); and by PRIN 2010-2011 (to M Maccarrone). We thank
Professor G Bernardi for his continuous support and encouragement. The
professional editorial work of Blue Pencil Science is also acknowledged.
1. Binkofski F, Seitz RJ, Arnold S, Classen J, Benecke R, Freund HJ. Thalamic metabolism
and corticospinal tract integrity determine motor recovery in stroke. Ann Neurol 1996; 39:
460–470.
2. Block F, Dihne M, Loos M. Inflammation in areas of remote changes following focal brain
lesion. Prog Neurobiol 2005; 75: 342–365.
3. Little JW, Halar E. Temporal course of motor recovery after Brown-Sequard spinal cord
injuries. Paraplegia 1985; 23: 39–46.
4. Roth EJ, Park T, Pang T, Yarkony GM, Lee MY. Traumatic cervical Brown-Sequard and
Brown-Sequard-plus syndromes: the spectrum of presentations and outcomes. Paraplegia
1991; 29: 582–589.
5. Alger BE, Kim J. Supply and demand for endocannabinoids. Trends Neurosci 2011; 34:
304–315.
6. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003; 4:
873–884.
7. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem
Pharmacol 2008; 160: 1–24.
8. Amantea D, Spagnuolo P, Bari M, Fezza F, Mazzei C, Tassorelli C et al. Modulation of the
endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection
afforded by 17beta-estradiol. FEBS J 2007; 274: 4464–4775.
9. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R et al.
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001; 413:
527–531.
10. Viscomi MT, Oddi S, Latini L, Pasquariello N, Florenzano F, Bernardi G et al. Selective CB2
receptor agonism protects central neurons from remote axotomy-induced apoptosis
through the PI3K/Akt pathway. J Neurosci 2009; 29: 4564–4570.
11. Chiurchiu V, Cencioni MT, Bisicchia E, De Bardi M, Gasperini C, Borsellino G et al.
Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in
multiple sclerosis. Ann Neurol 2013; 73: 626–636.
12. Arevalo-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic
action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003; 23:
2511–2516.
13. Velayudhan L, Van Diepen E, Marudkar M, Hands O, Suribhatla S, Prettyman R et al.
Therapeutic potential of cannabinoids in neurodegenerative disorders: a selective review.
Curr Pharm Des 2013; 20: 2218–2230.
14. Garcia-Ovejero D, Arevalo-Martin A, Petrosino S, Docagne F, Hagen C, Bisogno T et al.
The endocannabinoid system is modulated in response to spinal cord injury in rats.
Neurobiol Dis 2009; 33: 57–71.
15. Arevalo-Martin A, Garcia-Ovejero D, Molina-Holgado E. The endocannabinoid
2-arachidonoylglycerol reduces lesion expansion and white matter damage after spinal
cord injury. Neurobiol Dis 2010; 38: 304–312.
16. Arevalo-Martin A, Garcia-Ovejero D, Sierra-Palomares Y, Paniagua-Torija B,
Gonzalez-Gil I, Ortega-Gutierrez S et al. Early endogenous activation of CB1 and CB2
receptors after spinal cord injury is a protective response involved in spontaneous recovery.
PLoS One 2012; 7: e49057.
17. Adhikary S, Li H, Heller J, Skarica M, Zhang M, Ganea D et al. Modulation of inflammatory
responses by a cannabinoid-2-selective agonist after spinal cord injury. J Neurotrauma
2011; 28: 2417–2427.
18. Egan DA, Flumerfelt BA, Gwyn DG. Axon reaction in the red nucleus of the rat. Perikaryal
volume changes and the time course of chromatolysis following cervical and thoracic
lesions. Acta Neuropathol 1977; 37: 13–19.
19. Barron KD, Banerjee M, Dentinger MP, Scheibly ME, Mankes R. Cytological and
cytochemical (RNA) studies on rubral neurons after unilateral rubrospinal tractotomy: the
impact of GM1 ganglioside administration. J Neurosci Res 1989; 22: 331–337.
20. Kwon BK, Liu J, Messerer C, Kobayashi NR, McGraw J, Oschipok L et al. Survival and
regeneration of rubrospinal neurons 1 year after spinal cord injury. Proc Natl Acad Sci USA
2002; 99: 3246–3251.
21. Liu PH, Wang YJ, Tseng GF. Close axonal injury of rubrospinal neurons induced transient
perineuronal astrocytic and microglial reaction that coincided with their massive
degeneration. Exp Neurol 2003; 179: 111–126.
22. Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. Nat
Rev Mol Cell Biol 2012; 13: 780–788.
23. Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C, Kroemer G. Mechanisms of
cytochrome c release from mitochondria. Cell Death Differ 2006; 13: 1423–1433.
24. Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA
fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998;
273: 9357–9360.
25. Raghupathi R, Strauss KI, Zhang C, Krajewski S, Reed JC, McIntosh TK.
Temporal alterations in cellular Bax:Bcl-2 ratio following traumatic brain injury in the rat.
J Neurotrauma 2003; 20: 421–435.
26. Xu M, Ng YK, Leong SK. Neuroprotective and neurodestructive functions of nitric oxide
after spinal cord hemisection. Exp Neurol 2000; 161: 472–480.
27. Viscomi MT, Molinari M. Remote neurodegeneration: multiple actors for one play.
Mol Neurobiol 2014; 163: 1402–1410.
28. Tetzlaff W, Alexander SW, Miller FD, Bisby MA. Response of facial and rubrospinal
neurons to axotomy: changes in mRNA expression for cytoskeletal proteins and GAP-43.
J Neurosci 1991; 11: 2528–2544.
29. Jenkins R, Tetzlaff W, Hunt SP. Differential expression of immediate early genes in
rubrospinal neurons following axotomy in rat. Eur J Neurosci 1993; 5: 203–209.
30. Shohami E, Cohen-Yeshurun A, Magid L, Algali M, Mechoulam R. Endocannabinoids and
traumatic brain injury. Br J Pharmacol 2011; 163: 1402–1410.
31. Ashoton JC, Rahman RM, Nair SM, Sutherland BA, Glass M, Appleton I. Cerebral hypoxia-
ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2
receptor in the brain. Neurosci Lett 2007; 412: 114–117.
32. Oddi S, Latini L, Viscomi MT, Bisicchia E, Molinari M, Maccarrone M. Distinct regulation of
nNOS and iNOS by CB2 receptor in remote delayed neurodegeneration. J Mol Med 2012;
90: 371–387.
33. Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol
2010; 160: 467–479.
34. Onaivi ES. Commentary: Functional neuronal CB2 cannabinoid receptors in the CNS. Curr
Neuropharmacol 2011; 9: 205–208.
35. Onaivi ES, Ishiguro H, Gu S, Liu QR. CNS effects of CB2 cannabinoid receptors:
beyond neuro-immuno-cannabinoid activity. J Psychopharmacol 2012; 26: 92–103.
36. Feringa ER, McBride RL, Pruitt JN. Loss of neurons in the red nucleus after spinal cord
transection. Exp Neurol 1988; 100: 112–120.
37. Mori F, Himes BT, Kowada M, Murray M, Tessler A. Fetal spinal cord transplants rescue
some axotomized rubrospinal neurons from retrograde cell death in adult rats. Exp Neurol
1997; 143: 45–60.
38. Zhou L, Connors T, Chen DF, Murray M, Tessler A, Kambin P et al. Red nucleus neurons of
Bcl-2 over-expressing mice are protected from cell death induced by axotomy. Neuroreport
1999; 10: 3417–3421.
39. McBride RL, Feringa ER, Garver MK, Williams JK. Prelabeled red nucleus and
sensorimotor cortex neurons of the rat survive 10 and 20 weeks after spinal cord
transection. J Neuropathol Exp Neurol 1989; 48: 568–576.
40. Fukuoka T, Miki K, Yoshiya I, Noguchi K. Expression of beta-calcitonin gene-related
peptide in axotomized rubrospinal neurons and the effect of brain derived neurotrophic
factor. Brain Res 1997; 767: 250–258.
41. Carter LM, McMahon SB, Bradbury EJ. Delayed treatment with chondroitinase ABC
reverses chronic atrophy of rubrospinal neurons following spinal cord injury. Exp Neurol
2011; 228: 149–156.
42. Thuret S, Moon LD, Gage FH. Therapeutic interventions after spinal cord injury. Nat Rev
Neurosci 2006; 7: 628–643.
43. Kobayashi NR, Fan DP, Giehl KM, Bedard AM, Wiegand SJ, Tetzlaff W. BDNF and NT-4/5
prevent atrophy of rat rubrospinal neurons after cervical axotomy, stimulate GAP-43 and
Talpha1-tubulin mRNA expression, and promote axonal regeneration. J Neurosci 1997; 17:
9583–9595.
44. Kwon BK, Liu J, Lam C, Plunet W, Oschipok LW, Hauswirth W et al. Brain-derived
neurotrophic factor gene transfer with adeno-associated viral and lentiviral vectors
prevents rubrospinal neuronal atrophy and stimulates regeneration-associated gene
expression after acute cervical spinal cord injury. Spine 2007; 32: 1164–1173.
45. Liu Y, Himes BT, Murray M, Tessler A, Fischer I. Grafts of BDNF-producing fibroblasts
rescue axotomized rubrospinal neurons and prevent their atrophy. Exp Neurol 2002; 178:
150–164.
46. Maccarrone M, Finazzi-Agro A. The endocannabinoid system, anandamide and the
regulation of mammalian cell apoptosis. Cell Death Differ 2003; 10: 946–955.
CB2R in remote SCI damage
L Latini et al
13
Cell Death and Disease
47. Cohen-Yeshurun A, Trembovler V, Alexandrovich A, Ryberg E, Greasley PJ, Mechoulam R
et al. N-arachidonoyl-L-serine is neuroprotective after traumatic brain injury by reducing
apoptosis. J Cereb Blood Flow Metab 2011; 31: 1768–1777.
48. Molina-Holgado F, Pinteaux E, Heenan L, Moore JD, Rothwell NJ, Gibson RM.
Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are
mediated by phosphatidylinositol 3-kinase/AKT signaling. Mol Cell Neurosci 2005; 28: 189–194.
49. Howlett AC. Cannabinooid receptor signaling. Hand Exp Pharmacol 2005; 168: 53–79.
50. Elliott MB, Tuma RF, Amenta PS, Barbe MF, Jallo JI. Acute effects of a selective
cannabinoid-2 receptor agonist on neuroinflammation in a model of traumatic brain injury.
J Neurotrauma 2011; 28: 973–981.
51. Zhang M, Martin BR, Adler MW, Razdan RK, Jallo JI, Tuma RF. Cannabinoid CB(2)
receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion
model. J Cereb Blood Flow Metab 2007; 27: 1387–1396.
52. Rossignol S, Barriere G, Alluin O, Frigon A. Re-expression of locomotor function after
partial spinal cord injury. Physiology 2009; 24: 127–139.
53. Rossignol S, Frigon A. Recovery of locomotion after spinal cord injury: some facts and
mechanisms. Annu Rev Neurosci 2011; 34: 413–440.
54. Viscomi MT, D’Amelio M, Cavallucci V, Latini L, Bisicchia E, Nazio F et al. Stimulation of
autopghagy by rapamycin protects neurons from remote degeneration after acute focal
brain damage. Autophagy 2012; 8: 222–235.
55. Juan WS, Li HW, Chen YH, Chen HY, Hung YC, Tai SH et al. Optimal percoll concentration
facilitates flow cytometric analysis for annexin V/propidium iodine-stained ischemic brain
tissues. Cytometry A 2012; 81: 400–408.
56. Hamers FP, Koopmans GC, Joosten EA. CatWalk-assisted gait analysis in the assessment
of spinal cord injury. J Neurotrauma 2006; 23: 537–548.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution-NonCommercial-
NoDerivs 3.0 Unported License. The images or other third party
material in this article are included in the article’s Creative Commons
license, unless indicated otherwise in the credit line; if the material is
not included under the Creative Commons license, users will need to
obtain permission from the license holder to reproduce the material. To
view a copy of this license, visit http://creativecommons.org/licenses/
by-nc-nd/3.0/
Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)
CB2R in remote SCI damage
L Latini et al
14
Cell Death and Disease
